Biohaven Pharmaceutical Holding logo

BHVN - Biohaven Pharmaceutical Holding Share Price

$84.98 1.8  2.2%

Last Trade - 26/02/21

Large Cap
Market Cap £3.66bn
Enterprise Value £3.82bn
Revenue £20.5m
Position in Universe 1354th / 6715
Unlock BHVN Revenue
Relative Strength (%)
1m -3.93%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -15.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 54.0 249.4
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,Biohaven Pharmaceutical Holding Co Ltd revenues increasedfrom $0K to $28.5M. Net loss increased 45% to $549.1M.Revenues reflect an increase in demand for the Company'sproducts and services due to favorable market conditions.Higher net loss reflects General and administrative -Balancing v increase from $48.4M to $313.3M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


BHVN Revenue Unlock BHVN Revenue

Net Income

BHVN Net Income Unlock BHVN Revenue

Normalised EPS

BHVN Normalised EPS Unlock BHVN Revenue

PE Ratio Range

BHVN PE Ratio Range Unlock BHVN Revenue

Dividend Yield Range

BHVN Dividend Yield Range Unlock BHVN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BHVN EPS Forecasts Unlock BHVN Revenue
Profile Summary

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord. The Company also develops bispecific compounds that is designed to emulate or enhance the activity of biologics.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated September 25, 2013
Public Since May 4, 2017
No. of Shareholders: 57
No. of Employees: 647
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange New York Stock Exchange
Shares in Issue 59,939,166
Free Float (0.0%)
Eligible for
BHVN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BHVN
Upcoming Events for BHVN
Friday 30th April, 2021 Estimate
Biohaven Pharmaceutical Holding Company Ltd Annual Shareholders Meeting
Wednesday 5th May, 2021 Estimate
Q1 2021 Biohaven Pharmaceutical Holding Company Ltd Earnings Release
Frequently Asked Questions for Biohaven Pharmaceutical Holding
What is the Biohaven Pharmaceutical Holding share price?

As of 26/02/21, shares in Biohaven Pharmaceutical Holding are trading at $84.98, giving the company a market capitalisation of £3.66bn. This share price information is delayed by 15 minutes.

How has the Biohaven Pharmaceutical Holding share price performed this year?

Shares in Biohaven Pharmaceutical Holding are currently trading at $84.98 and the price has moved by 0.108k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biohaven Pharmaceutical Holding price has moved by 60.61% over the past year.

What are the analyst and broker recommendations for Biohaven Pharmaceutical Holding?

Of the analysts with advisory recommendations for Biohaven Pharmaceutical Holding, there are there are currently 4 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Biohaven Pharmaceutical Holding is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Biohaven Pharmaceutical Holding next release its financial results?

Biohaven Pharmaceutical Holding is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Biohaven Pharmaceutical Holding dividend yield?

Biohaven Pharmaceutical Holding does not currently pay a dividend.

Does Biohaven Pharmaceutical Holding pay a dividend?

Biohaven Pharmaceutical Holding does not currently pay a dividend.

When does Biohaven Pharmaceutical Holding next pay dividends?

Biohaven Pharmaceutical Holding does not currently pay a dividend.

How do I buy Biohaven Pharmaceutical Holding shares?

To buy shares in Biohaven Pharmaceutical Holding you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Biohaven Pharmaceutical Holding?

Shares in Biohaven Pharmaceutical Holding are currently trading at $84.98, giving the company a market capitalisation of £3.66bn.

Where are Biohaven Pharmaceutical Holding shares listed? Where are Biohaven Pharmaceutical Holding shares listed?

Here are the trading details for Biohaven Pharmaceutical Holding:

Country of listing: United States
Exchange: NYQ
Ticker Symbol: BHVN
What kind of share is Biohaven Pharmaceutical Holding?

Based on an overall assessment of its quality, value and momentum, Biohaven Pharmaceutical Holding is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Biohaven Pharmaceutical Holding share price forecast 2021?

Shares in Biohaven Pharmaceutical Holding are currently priced at $84.98. At that level they are trading at 0.61% discount to the analyst consensus target price of 0.00.

Analysts covering Biohaven Pharmaceutical Holding currently have a consensus Earnings Per Share (EPS) forecast of -12.352 for the next financial year.

How can I tell whether the Biohaven Pharmaceutical Holding share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biohaven Pharmaceutical Holding. Over the past six months, the relative strength of its shares against the market has been 28.91%. At the current price of $84.98, shares in Biohaven Pharmaceutical Holding are trading at 13.38% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Biohaven Pharmaceutical Holding PE Ratio?

We were not able to find PE ratio data for Biohaven Pharmaceutical Holding.

Who are the key directors of Biohaven Pharmaceutical Holding?

Biohaven Pharmaceutical Holding's management team is headed by:

Vlad Coric - CEO
Robert Berman - OTH
James Engelhart - CFO
John Tilton - OTH
Charles Conway - CSO
Kimberly Gentile - SVP
Gregory Bailey - DRC
John Childs - DRC
Julia Gregory - IND
Thomas Lynch - CHM
Michael Heffernan - DRC
Elyse Stock - OTH
William Jones - OTH
Robert Hugin - DRC
Who are the major shareholders of Biohaven Pharmaceutical Holding?

Here are the top five shareholders of Biohaven Pharmaceutical Holding based on the size of their shareholding:

Capital International Investors Investment Advisor
Percentage owned: 8.89% (5.33m shares)
Capital World Investors Investment Advisor
Percentage owned: 7.76% (4.65m shares)
American Funds Growth Fund of America Mutual Fund
Percentage owned: 7.24% (4.34m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.09% (3.05m shares)
American Funds SMALLCAP World Fund Mutual Fund
Percentage owned: 4.47% (2.68m shares)
Similar to BHVN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.